Prospective, single arm Phase 3 trial with 43 sites worldwide (NCT03212521) aiming to evaluate the efficacy and safety of G/P (300/120mg) QD administered for 8 weeks in treatment-naïve adults with chronic HCV genotypes (GT) 1-6 infection and Aspartate aminotransferase to platelet ratio index (APRI) ≤1. Here, we report preliminary data from this study.